Q3 2025 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2025-11-14 · accession 0001193125-25-281790
The Brief · Omega Fund Management, LLC · Q3 2025
AI · grounded in 13F
Omega Fund Management, LLC established a new position in BridgeBio Oncology Therapeutics Inc. BBOT valued at $38.09M. The fund also added a new position in ImageneBio, Inc. IMA for $3.71M. Offsets included closing positions in Lexeo Therapeutics LXEO for -$4.76M, Ikena Oncology for -$3.01M, and Immunic Inc. VTLUSD for -$1.25M. Additionally, the fund reduced its stake in Replimune Group REPL by 87.41%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G52441105 | KMTS | Kestra Med Technologies Ltd | $39.1M | 17.6% | 1,645,893 | Common | SOLE |
| 08659B102 | BBNX | Beta Bionics Inc. | $38.2M | 17.2% | 1,920,125 | Common | SOLE |
| 107924102 | BBOT | BridgeBio Oncology Therapeutics Inc. | $38.1M | 17.1% | 3,289,661 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc. | $34.8M | 15.7% | 2,204,650 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio | $32.7M | 14.7% | 8,831,089 | Common | SOLE |
| 91678A107 | UPB | Upstream Bio Inc. | $25.5M | 11.5% | 1,356,293 | Common | SOLE |
| 45175G207 | IMA | ImageneBio, Inc. | $3.7M | 1.67% | 455,361 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $3.6M | 1.62% | 526,357 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $3.0M | 1.35% | 843,750 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $2.6M | 1.17% | 653,223 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $1.0M | 0.47% | 248,672 | Common | SOLE |
| 29286M113 | — | enGene Holdings Inc. | $63,438 | 0.03% | 89,702 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.